Pro Share Advisors LLC Incyte Corp Transaction History

Pro Share Advisors LLC

$39.7 Billion
Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Incyte Corp stock. As of the latest transaction made, Pro Share Advisors LLC holds 55,191 shares of INCY stock, worth $3.92 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

55,191

Previous 63,017 12.42%

Holding current value

$3.92 Million

Previous $3.82 Million 4.5%

% of portfolio

0.01%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$57.33 - $68.61 $448,664 - $536,941	-7,826 Reduced 12.42%	55,191 $3.65 Million
Q2 2024 Aug 13, 2024	SELL	$51.18 - $63.75 $3,531 - $4,398	-69 Reduced 0.11%	63,017 $3.82 Million
Q1 2024 May 08, 2024	BUY	$56.55 - $66.59 $448,158 - $527,725	7,925 Added 14.37%	63,086 $3.59 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $142,240 - $175,046	-2,727 Reduced 4.71%	55,161 $3.46 Million
Q3 2023 Nov 13, 2023	SELL	$57.77 - $65.93 $139,687 - $159,418	-2,418 Reduced 4.01%	57,888 $3.34 Million
Q2 2023 Aug 10, 2023	SELL	$60.95 - $75.51 $15,847 - $19,632	-260 Reduced 0.43%	60,306 $3.75 Million
Q1 2023 May 11, 2023	BUY	$70.23 - $86.01 $19,875 - $24,340	283 Added 0.47%	60,566 $4.38 Million
Q4 2022 Feb 02, 2023	SELL	$67.18 - $84.11 $197,576 - $247,367	-2,941 Reduced 4.65%	60,283 $4.84 Million
Q3 2022 Nov 04, 2022	SELL	$66.18 - $82.86 $101,189 - $126,692	-1,529 Reduced 2.36%	63,224 $4.21 Million
Q2 2022 Aug 01, 2022	SELL	$66.18 - $83.18 $1.31 Million - $1.64 Million	-19,738 Reduced 23.36%	64,753 $4.92 Million
Q1 2022 May 10, 2022	SELL	$66.02 - $79.71 $690,635 - $833,846	-10,461 Reduced 11.02%	84,491 $6.71 Million
Q4 2021 Feb 08, 2022	SELL	$63.34 - $74.11 $14.8 Million - $17.4 Million	-234,376 Reduced 71.17%	94,952 $6.97 Million
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $2.43 Million - $2.97 Million	35,317 Added 12.01%	329,328 $22.7 Million
Q2 2021 Aug 13, 2021	BUY	$79.87 - $87.53 $48,401 - $53,043	606 Added 0.21%	294,011 $24.7 Million
Q1 2021 May 14, 2021	BUY	$76.02 - $100.5 $2.85 Million - $3.77 Million	37,465 Added 14.64%	293,405 $23.8 Million
Q4 2020 Feb 09, 2021	BUY	$80.74 - $97.7 $2.44 Million - $2.95 Million	30,237 Added 13.4%	255,940 $22.3 Million
Q3 2020 Nov 13, 2020	BUY	$85.07 - $109.69 $2.68 Million - $3.46 Million	31,501 Added 16.22%	225,703 $20.3 Million
Q2 2020 Aug 03, 2020	BUY	$74.18 - $108.93 $1.07 Million - $1.57 Million	14,408 Added 8.01%	194,202 $20.2 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $4.34 Million - $5.91 Million	-68,736 Reduced 27.66%	179,794 $13.2 Million
Q4 2019 Feb 12, 2020	BUY	$73.04 - $95.72 $465,995 - $610,693	6,380 Added 2.63%	248,530 $21.7 Million
Q3 2019 Nov 12, 2019	BUY	$72.82 - $86.52 $118,186 - $140,421	1,623 Added 0.67%	242,150 $18 Million
Q2 2019 Aug 13, 2019	SELL	$73.52 - $88.7 $384,509 - $463,901	-5,230 Reduced 2.13%	240,527 $20.4 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $152,035 - $210,902	2,392 Added 0.98%	245,757 $21.1 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $1.32 Million - $1.57 Million	22,495 Added 10.18%	243,365 $15.5 Million
Q3 2018 Nov 14, 2018	SELL	$61.75 - $74.23 $208,468 - $250,600	-3,376 Reduced 1.51%	220,870 $15.3 Million
Q2 2018 Aug 13, 2018	SELL	$60.85 - $83.98 $1.82 Million - $2.51 Million	-29,845 Reduced 11.75%	224,246 $15 Million
Q1 2018 May 14, 2018	BUY	$83.06 - $100.98 $850,700 - $1.03 Million	10,242 Added 4.2%	254,091 $21.2 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $3.48 Million - $4.34 Million	37,240 Added 18.02%	243,849 $23.1 Million
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $2.05 Million - $2.6 Million	18,816 Added 10.02%	206,609 $24.1 Million
Q2 2017 Aug 11, 2017	BUY	N/A	187,793	187,793 $23.6 Million

Others Institutions Holding INCY

# of Institutions

642

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Incyte Corp Transaction History